ADME & PK Services

Cyprotex offer a comprehensive range of experimental ADME and in silico prediction services:

A panel of cost-effective, high quality ADME screening services which deliver critical information on absorption (PAMPA, Caco-2 permeability and MDR1-MDCK permeability), distribution (in vitro transporters, plasma protein binding), metabolism (cytochrome P450 inhibition, time dependent inhibition ,metabolic stability, microsomal binding and reaction phenotyping) and physicochemical properties (solubility, lipophilicity and chemical stability).

A range of bespoke high quality ADME and DMPK experimental services designed to meet the needs of later stage development projects. It includes a range of absorption (P-gp inhibition), distribution (blood to plasma ratio and brain tissue binding), drug metabolism (cytochrome P450 induction, K_i determination, k_inact/K_I determination, UGT1A1 inhibition and metabolite profiling and identification) and physicochemical (pKa and logP) services as well as a pharmacokinetics and bioanalysis service. 

Expertise in predictive modelling using PBPK and QSAR techniques. We have developed our own proprietary software for the prediction of in vivo pharmacokinetics (Cloe® PK) and human intestinal absorption (Cloe^® HIA) from in vitro ADME and physicochemical data. These products are available to our customers via our web portal, Cloe^® Gateway.